Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
ImmuneSensor Therapeutics Inc.
Bristol-Myers Squibb
University of Oxford
Exelixis
Bristol-Myers Squibb
Royal Marsden NHS Foundation Trust
Bristol-Myers Squibb
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Case Comprehensive Cancer Center
University of California, San Diego
Molecular Templates, Inc.
Hoosier Cancer Research Network
Taris Biomedical LLC
Barbara Ann Karmanos Cancer Institute
University of Michigan Rogel Cancer Center
Abramson Cancer Center at Penn Medicine
Sumitomo Pharma America, Inc.
OHSU Knight Cancer Institute
Aravive, Inc.
Mirati Therapeutics Inc.
Bristol-Myers Squibb
Nektar Therapeutics
Nektar Therapeutics
Bristol-Myers Squibb
Bristol-Myers Squibb
X4 Pharmaceuticals
Duke University
Apollomics (Australia) Pty. Ltd.
AIO-Studien-gGmbH
University of Chicago
National Cancer Institute (NCI)
Western Regional Medical Center
M.D. Anderson Cancer Center